Director Global Access Strategy Pricing Precision Medicines and Lung Cancer

The Global Access Strategy and Pricing (GASP) Precision Medicine & Lung Cancer Director role directly impacts the ability to achieve business objectives by supporting the development of strategic guidance on access, pricing, optimal reimbursement, launch sequencing, patient value, and evidence generation for the Precision Medicine & Lung Cancer franchise.

The Precision Medicine & Lung Cancer franchise is one of the prioritized Oncology franchises and consists of products recently post DP3, with pre-DP3 indications, and pre-launch and in-line products. The franchise includes the following products: Braftovi, Mektovi, Lorbrena, Xalkori, Sigvotatug Vedotin and PDL1V. The objective for the franchise strategy is to advance the treatment of lung cancer through next-generation backbones of treatment and novel combinations from our internal portfolio and with external combination partners.

This position will function with a ‘One Global Access and Value’ mindset and work in an aligned manner with the Breast GASP team, other GAV colleagues (USMA, HV&E), and Country Access & Value colleagues. The role will be most heavily focused on  indications for Braftovi and Mektovi. This person will support the advancement of the integrated value and access strategy (IVAS) in partnership with the cross functional team and aligned to the brand strategy. The IVAS will optimize the long-term value of the products by optimizing the pricing & access strategy including indication launch sequence and evidence generation plans. The position reports to the GASP Precision Medicine & Lung Cancer Team Lead within GAV.
 

ROLE RESPONSIBILITIES

• Lead generation of payer insights and support the translation into clear and cohesive integrated value and access, pricing and evidence generation strategies for key markets to support the Precision Medicine & Lung Cancer Franchise
• Provide subject matter expertise and support critical strategic discussions at Senior Leadership forums
• Deliver clear recommendations relating to payer strategy, pricing and reimbursement, analogue case studies, evidence generation, data collection and value proposition
• Participate in virtual cross functional teams including representing GAV at Commercial Subteams, and at the GPT. Coordinate and lead projects related to specific asset threats and opportunities

Generate & synthesize payer insights

• Maintain in-depth understanding of payer regulations, including novel-novel combinations, fixed dose combinations, and needs of all types of payers (e.g. HTA agencies, institutions and patients) in key Pfizer markets
• Knowledgeable about US oncology access & pricing landscape, IDM markets, China, Japan, HTA/payer requirements and EU JCA
• Support assessment and communication of external access trends to anticipate potential challenges and opportunities for the Precision Medicine & Lung franchise
• Gather and synthesize feedback for development programs with health technology assessment agencies, payers, and relevant patient associations

Develop payer value proposition and drive market access strategy

• Support the development of clear and cohesive access, pricing and evidence generation strategy to optimize value of the Precision Medicine & Lung Franchise 
• Lead discussions with Country Health & Value and Payer Channel Access Leads at critical junctures to ensure local insights are integrated into global plans that optimize long-term value for Precision Medicine & Lung Franchise
• Provide input into clinical development plans, market access and pricing strategies and recommendations, early HTA advice, early economic models, and evidence generation plans via the Integrated Value & Access Plan
• Support alignment efforts with Commercial, CSI, Clinical, Medical, and Asset teams to ensure clinical trial design, real world evidence plan, and commercial strategies reflect payer insights and align with Bold Moves in order to maximize value of the Precision Medicine & Lung Franchise
• Support discussions and early buy-in discussions with senior leadership on price and market access strategy and recommendations to support key business decision points
• Support development of the IVAS, value proposition and value-based agreement strategy and buy-in from cross-functional stakeholders
• Develop pricing & market access product and country assessments, and run country workshops
• Support analyses and recommendations in partnership with HV&E to influence clinical trial design recommendations (e.g. endpoints, comparators, PROs), development of early economic model, and generation of supplemental evidence (e.g. comparative-effectiveness studies leveraging real